Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Bhushan Nagar(McGill University), John Kuriyan(Vanderbilt University), W. Todd Miller(Memorial Sloan Kettering Cancer Center), Thomas H. Schindler(University Hospital of Geneva), Darren R. Veach, William G. Bornmann(Memorial Sloan Kettering Cancer Center), Bayard D. Clarkson(Memorial Sloan Kettering Cancer Center), Patricia Pellicena(State University of New York)
PubMed
August 1, 2002
Cited by 941

Related Papers

Crystallographic <i>R</i> Factor Refinement by Molecular Dynamics
|Science|1987|2k
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
|Science|2000|1.8k
The Conformational Plasticity of Protein Kinases
|Cell|2002|1.8k
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
|Cell|2006|1.6k
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k